Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Conditions
- Rectal Adenocarcinoma
- Stage IIA Rectal Cancer
- Stage IIB Rectal Cancer
- Stage IIC Rectal Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Rectal Cancer
Interventions
- OTHER: Laboratory Biomarker Analysis
- DRUG: Regorafenib
Sponsor
Roswell Park Cancer Institute
Collaborators